Candel Therapeutics, Inc.
$7.22
▲
0.4%
2026-04-21 05:52:00
www.candeltx.com
NGM: CADL
Explore Candel Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$466.58 M
Current Price
$7.22
52W High / Low
$7.25 / $4.34
Stock P/E
—
Book Value
$0.95
Dividend Yield
—
ROCE
-41.46%
ROE
-64.58%
Face Value
—
EPS
$-0.72
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
-0.81
Debt / Equity
94.44
Current Ratio
13.49
Quick Ratio
13.49
Forward P/E
-7.55
Price / Sales
—
Enterprise Value
$283.09 M
EV / EBITDA
-5.98
EV / Revenue
—
Rating
None
Target Price
$18.88
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Context Therapeutics Inc. | $2.26 | — | $223.27 M | — | -65.65% | -46.39% | $3.62 / $0.49 | $0.66 |
| 2. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 3. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 4. | Apogee Therapeutics, Inc. | $90.92 | — | $6.41 B | — | -31.41% | -31.57% | $95.31 / $31.38 | $13.21 |
| 5. | CorMedix Inc. | $7.58 | 3.58 | $584.18 M | — | 23.03% | 66.56% | $17.43 / $6.13 | $5.11 |
| 6. | Decoy Therapeutics Inc. | $5.89 | — | $3.09 M | — | -379.33% | -3.38% | $415.8 / $5.4 | $11.07 |
| 7. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.66 M | -13.21 M | -11.18 M | -8.13 M | -8.14 M |
| Net Profit | -29.5 M | -11.27 M | -4.8 M | 7.38 M | -14.07 M |
| EPS in Rs | -0.4 | -0.15 | -0.07 | 0.1 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.12 M |
| Operating Profit | -48.18 M | -33.37 M | -38.39 M | -34.67 M |
| Net Profit | -38.18 M | -55.18 M | -37.94 M | -18.79 M |
| EPS in Rs | -0.52 | -0.75 | -0.52 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 125.19 M | 106.87 M | 41.2 M | 77.69 M |
| Total Liabilities | 73.27 M | 40.54 M | 28.46 M | 29.98 M |
| Equity | 51.92 M | 66.33 M | 12.74 M | 47.71 M |
| Current Assets | 121.39 M | 103.8 M | 36.8 M | 71.94 M |
| Current Liabilities | 9 M | 37.53 M | 14.18 M | 5.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -38.31 M | -27.02 M | -34.24 M | -31.42 M |
| Investing CF | -0.56 M | -0.02 M | -0.28 M | -1.3 M |
| Financing CF | 56.1 M | 94.28 M | -0.12 M | 19.97 M |
| Free CF | -38.9 M | -27.04 M | -34.7 M | -32.72 M |
| Capex | -0.59 M | -0.02 M | -0.46 M | -1.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -45.44% | -101.87% | — | — |
| Profit Margin % | — | — | -15035.2% | — |
| Operating Margin % | — | — | -27739.2% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -13046.4% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.